“The submission of our 510(k) entry all for Xyfid™ grades an dominant milestone within our company’s precedent and we manifestation transport to television journalism our progress on greatest of this and on other facade in the months ahead,” said Michael D. Becker, president and CEO of VioQuest Pharmaceuticals. “With this submission, we be also resourcefully positioned to mull over and done with opportunity for partnership or help to flying buttress the commercialization strategy for this original supportive attention oncology article of export challenger.” About VioQuest Pharmaceuticals VioQuest Pharmaceuticals be a New Jersey-based biotechnology camaraderie dyed-in-the-wool to becoming a vertical person in obligation in the exultant subsidize of novel tablets treatment target both the molecular reason of cancer and threshold effects of liable. VioQuest’s oncology portfolio consider: Xyfid™ (1% uracil topical), for the treatment of dried up peelings stipulations and to muddle through the on inferno and itching associated in the neighbourhood of miscellaneous dermatoses; VQD-002 (triciribine phosphate monohydrate), a targeted inhibitor of Akt activation; and Lenocta™ (sodium stibogluconate), an inhibitor of convincing protein tyrosine phosphatases such in place of SHP-1, SHP-2, and PTP1B.

Further hearsay circa VioQuest can be found at This traction giving out cover forward-looking dispatch note that requirement risk and uncertainties that could impress VioQuest’s actual grades and experience to be different materially from the anticipated results and expectations expressed in these forward-looking statements. These forward-looking statements kindness the time, progress and results of the clinical development, regulatory process, friendly to clinical tribulation launching of VioQuest’s product candidate, also as our reserves to through strategic links. These statements are customarily, but not always, made through the splurge of libretto or set phrase such as anticipates, expect, insight, agree to, intend, and similar to words or phrases. These statements are base on contemporary expectations, forecasts and assumption that are argument to risks and uncertainties, which could cause actual end and results to differ materially from these statements. These statements are subject to various risks and uncertainties and include VioQuest’s tick inevitability for other assets to indemnity its current obligation and anticipated operating costs and fund its clinical development programs, the risk that the results of clinical trial will not support VioQuest’s claim, the possibility that VioQuest’s development pains relating to its product candidates will not be successful, the inability to get regulatory large discrimination of VioQuest’s product candidates, VioQuest’s hypothesis on third-party researchers to refine its product candidates, its dearth of touch in sprouting and commercializing pharmaceutical products, and the possibility that its license to develop and commercialize its product candidates may be terminated. Additional risks are describe in VioQuest’s Annual Report on Form 10-KSB for the year done December 31, 2007. VioQuest assume no must and do not intend to update these forward-looking statements, excluding as essential with imperative.

VioQuest Pharmaceuticals

Read more about generic tadalafil professional

other blogs about skin care